FIELD: biotechnology.
SUBSTANCE: described is a method for vaccinating a subject with brain cancer, including: (i) production of viable tumour tissue from the subject, wherein tumour tissue is surgically removed from the subject; (ii) collection of tumour tissue in a sterile trap; (iii) collection of adhesive cells from the tumour tissue; (iv) encapsulation of the collected cells in a biodiffusion chamber together with an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide (IGF-1R AS ODN) with the sequence SEQ ID NO:1; (v) irradiation of the chamber, and (vi) implantation of the chamber to the subject, wherein an immune response against brain cancer is received, wherein the subject is vaccinated using 1 to 50 chambers for 24 to 96 hours. Also presented is a corresponding biodiffusion chamber.
EFFECT: invention expands the range of agents for treating cancer.
22 cl, 98 dwg, 4 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH HPV | 2019 |
|
RU2799784C2 |
| METHODS OF PREDICTING RESPONSE OF TRIPLE NEGATIVE MAMMARY GLAND CANCER TO THERAPY | 2011 |
|
RU2558931C2 |
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706967C2 |
| COMBINED IMMUNOTHERAPEUTIC APPROACH TO CANCER TREATMENT | 2015 |
|
RU2716821C2 |
| MACROPHAGE ACTIVATION MODULATION | 2012 |
|
RU2639553C2 |
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706959C2 |
| VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT | 2016 |
|
RU2747296C2 |
| CELLULAR SYSTEM FOR TARGETED DELIVERY OF A PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL | 2016 |
|
RU2771323C2 |
| COMPOSITIONS FOR T-CELL THERAPY WITH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2018 |
|
RU2819805C2 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
